Nasopharyngeal carcinoma (NPC) is a non-lymphomatous, squamous-cell carcinoma that occurs in the epithelial lining of the nasopharynx. It has a distinct epidemiology, aetiology ([@bib5]) and clinical manifestation ([@bib38]) compared with other cancers, including other types of head and neck cancers. The highest rates of incidence occur in Southeast Asia, especially in Southern China, where the incidence of NPC can be as high as 20 to 30 per 100 000 ([@bib3]). In contrast, NPC is relatively rare in Europe and the United States, where the incidence is only 0.5 to 2 per 100 000 ([@bib11]).

An accurate staging system is critical for defining prognosis, determining appropriate treatment and evaluating treatment outcomes. The introduction of the sixth edition of the TNM staging system (TNM6th) for NPC ([@bib12]), jointly adopted by the International Union against Cancer (UICC) and American Joint Committee for Cancer (AJCC), was an important landmark. Subsequent retrospective studies showed that nasal cavity/oropharynx involvement without parapharyngeal extension (T2a by TNM6th) had a similar, favourable prognosis to T1 ([@bib19]; [@bib24]; [@bib28]); anatomic masticator space involvement including the medial and lateral pterygoid muscles had a similar prognosis to T4 ([@bib36]); and retropharyngeal lymph node (RP-LN) metastasis, regardless of laterality, had a poorer prognosis than node-negative disease ([@bib35]; [@bib37]). Therefore, the recent seventh edition of the UICC/AJCC (TNM7th) ([@bib9], [@bib10]) revised the criteria based on these findings. However, reverse evidence suggested that T2a patients should not be in the same prognostic group as T1 patients ([@bib25]); studies ([@bib8]; [@bib30]; [@bib34]) revealed that RP-LN metastasis did not influence overall survival (OS) and distant metastasis-free survival (DMFS). In addition, with the enhanced locoregional control of intensity-modulated radiotherapy (IMRT), it needs a full reappraisal to see whether the prognosis of the medial and lateral pterygoid muscles involvement remains to be similar to T4. Finally, as NPC is especially prevalent in Southern China ([@bib3]), the Chinese 2008 Staging System for NPC (TNMc2008) ([@bib4]) was released by the Chinese Committee for Staging of Nasopharyngeal Carcinoma, based on the Chinese 1992 Staging System.

Although TNM7th is now internationally recommended, TNMc2008 is widely used in the most endemic area -- Mainland China. This discrepancy is because scientific evidence has not satisfactorily justified the use of these criteria in cancer staging. It greatly influences treatment assessment, and comparisons and clinical cooperation between different centres. Identification of the most useful staging criteria for therapeutic decision making is warranted. Few carefully designed studies have formally compared the two editions of UICC/AJCC staging system and the Chinese 2008 staging system to determine which is most useful for therapeutic decision making. Therefore, we performed this study to comprehensively evaluate and directly compare the three NPC staging systems -- TNM6th, TNM7th and TNMc2008. In addition, considering the discrepancies between TNM6th, TNM7th and TNMc2008 and proposals from studies ([@bib15]; [@bib36]; [@bib21]; [@bib6], [@bib7]; [@bib22]; [@bib34]), we constructed staging models, compared them with the existing staging systems and ultimately proposed and confirmed some modifications for NPC staging system.

Materials and methods
=====================

Patients
--------

The study was reviewed and approved by the Human Ethics Approval Committee at Sun Yat-sen University Cancer Center. We retrospectively reviewed the medical records of 2333 patients with newly diagnosed, biopsy-proven, non-metastatic NPC hospitalised at our centre. We classified them into three cohorts. The first one -- IMRT cohort -- involved 941 patients (714 men, 227 women; median age, 46 years; range, 13--84 years; histological type: I, 1; II, 35; and III, 905) treated with IMRT between January 2003 and December 2009. The second one -- CRT cohort -- involved 1392 patients (1054 men, 338 women; median age, 45 years; range, 12--80 years; type: I, 5; II, 70; and III, 1317) treated with conventional radiotherapy (CRT) between January 2005 and December 2006. To validate the results of the IMRT and CRT cohorts, we enrolled 1673 patients with NPC treated between January 2005 and December 2006, irrespective of radiation techniques, as the third cohort (1269 men, 404 women; median age, 45 years; range, 12--80 years; type: I, 6; II, 91; and III, 1576; IMRT, 281 (16.8%), CRT, 1392 (83.2%)).

All included patients had complete pretreatment evaluation including patient history, physical examination, haematology and biochemistry profiles, fiberoptic nasopharyngoscopy with biopsy, magnetic resonance imaging (MRI) of the nasopharynx and neck, chest radiography, abdominal sonography and Technetium-99m-methylene diphosphonate (Tc-99-MDP) whole-body bone scan. In addition, a total of 199 (8.5% of 2333) patients underwent 18F-fluorodeoxyglucose positron emission tomography and computed tomography (PET/CT) -- 132 (14.0% of 941), 67 (4.8% of 1392) and 141 (8.4% of 1673) patients in the IMRT, CRT and the third cohort, respectively. Two radiologists independently reviewed all the images based on the MRI diagnosis criteria (see [Supplementary Information](#sup1){ref-type="supplementary-material"}) ([@bib17]) and restaged all the patients according to the criteria of the three staging systems ([Table 1](#tbl1){ref-type="table"}). Any disagreements were resolved by consensus.

All patients were treated by definitive IMRT or CRT with or without chemotherapy; the radiation techniques and chemotherapy regimens have been described previously ([@bib27]; [@bib23]; [@bib7]). Considering the heterogeneous chemotherapy regimens, subgroup analysis by chemotherapy (induction chemotherapy (IC); concomitant chemotherapy (CC); IC plus CC; and CC plus adjuvant chemotherapy) was conducted in each cohort. In addition, stratified analysis by age and gender was also performed.

Patients were examined every 3--6 months during the first 3 years, with follow-up examinations every 6--12 months thereafter or until death. Patients without recent examination tests in the medical records were followed up by telephone call till June of this year. Within the median follow-up duration (from the first day of therapy) of 57 months (range, 3--124 months), 74 months (range, 2--102 months) and 74 months (range, 2--102 months) for the IMRT, CRT and the third cohort, 102 out of 941 (10.8%), 143 out of 1392 (10.3%) and 174 out of 1673 (10.4%) patients were lost to follow-up, with 200, 435 and 510 cases of treatment failure (locoregional relapse, distant metastasis or death from any cause, whichever was first; the diagnosing criteria were available in [Supplementary Information](#sup1){ref-type="supplementary-material"}), respectively.

Statistical analysis
--------------------

Statistical analyses were performed using SAS version 9.1 (SAS Institute, Cary, NC, USA) and R version 3.0.0 ([www.r-project.org](http://www.r-project.org)). Prognostic stratification of failure-free survival (FFS; time from the first day of therapy to the day of treatment failure) by T-classification, N-classification and clinical stage groups was evaluated using Akaike information criterion (AIC) ([@bib1]) and Harrell\'s concordance index (c-index) ([@bib13]). The AIC was analysed using Cox proportional hazards regression model with other prognostic covariates, including age (continuous), gender, histological type, chemotherapy type and radiation technique. The optimum model -- the simplest effective model with the smallest information loss when predicting outcome -- gives the lowest AIC value. Harrell\'s c-index was also calculated as a measure of predictive accuracy of survival outcome; a c-index of 0.5 indicates accuracy similar to random guessing, and that of 1.0 indicates 100% predictive accuracy. Actuarial FFS rates were estimated by the Kaplan--Meier method and survival curves were compared using the log-rank test. Multivariate analyses with covariates such as age and gender were used to calculate hazard ratios (HRs) by the Cox proportional hazards model. In addition, T-classification was included as a covariate in analyses of N-classification, and vice versa. Two-tailed *P-*values of \<0.05 were considered statistically significant.

Results
=======

Comparison of the TNM6th, TNM7th and TNMc2008 staging systems
-------------------------------------------------------------

Generally speaking, the most obvious differences in T-classification among the three staging systems are the distributions of nasal cavity or oropharynx involvement, paranasal sinuses extension and medial and lateral pterygoid muscle involvement. With respect to N-classification, both TNM6th and TNM7th are graded according to the palpation-based greatest diameter of tumour-positive lymph nodes, and TNM6th disregards RP-LNs, whereas TNMc2008 is classified using MRI-determined lymph node levels and sizes, extranodal neoplastic spread (ENS) and RP-LNs. In [Supplementary Table 1](#sup1){ref-type="supplementary-material"}, we have listed stage migration because of the differences among the three TNM systems for the IMRT and CRT cohorts. There were high proportions of N-classification changes (\>20% cases) between TNM6th or TNM7th and TNMc2008, and ∼10% of cases had T-classification changes across the three systems.

The ability of each TNM staging system to stratify FFS is presented in [Table 2](#tbl2){ref-type="table"}. In the IMRT cohort, both AIC and c-index values revealed that TNM6th had superior prognostic value by T-classification (T1/T2/T3/T4), followed by TNMc2008 or TNM7th, whereas the prognostic value by N-classification (N0/N1/N2/N3) was highest for TNMc2008 followed by TNM7th and TNM6th. However, different trends were observed in the CRT cohort; TNMc2008 had superior prognostic value by both T-classification and N-classification, followed by TNM6th and then TNM7th. The results of the CRT cohort were validated in the third cohort. With regard to clinical stage group (I/II/III/IV), TNM6th had superior prognostic value in the IMRT cohort, followed by TNM7th and TNMc2008. In the CRT cohort, TNMc2008 was superior to TNM6th and TNM7th; this result was again validated in the third cohort.

In addition, we compared the prognostic value of the three staging systems in predicting FFS for the chemotherapy subgroups in each cohort. As shown in [Table 3](#tbl3){ref-type="table"}, in the IMRT cohort, the results of the RT alone set, CC set and IC plus CC set consistently demonstrated the highest prognostic value for T-classification of TNM6th and N-classification of TNMc2008, similar to the results obtained in the whole IMRT cohort. In the CRT cohort, the results of the RT alone set, IC set and CC set demonstrated the best prognostic value for T-classification and N-classification of TNMc2008, similar to the entire CRT cohort. However, in particular, in the IC plus CC set of the CRT cohort, the prognostic value of T-classification of TNM6th, rather than TNMc2008, was superior to the other staging systems, which was quite consistent with the results of the IMRT cohort. The N-classification of TNMc2008 still had the most favourable prognostic value in the IC plus CC set of the CRT cohort. When analysed by the multiple chemotherapy subgroups, the third cohort validated the results of the CRT cohort.

In the stratums by age (⩽60 and \>60 years old) and gender, the results of comparison were quite similar to those in the overall cohort, respectively ([Table 4](#tbl4){ref-type="table"}).

Comparison of staging models
----------------------------

Given the above differences between patients treated with IMRT and CRT, and the recent recommendation of IMRT as the standard treatment by the Head and Neck Cancers of the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (Version 2, 2013; [www.nccn.org](http://www.nccn.org)), we constructed 10 T-classification models and 4 N-classification models with the 941 patients in the IMRT cohort. The main changes of classification criteria from the based staging systems to our staging models were as follows ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). For T-classification, the first model (model-Ta1) downstaged oropharynx and/or nasal cavity involvement in TNM6th to T1, and the second (model-Ta2) downstaged oropharynx and/or nasal cavity involvement in TNMc2008 to T1. The third (model-Tb) classified oropharynx, nasal cavity and parapharyngeal extension as T1 *vs* TNM6th. The forth (model-Tc1) and fifth (model-Tc2) categorised paranasal sinus involvement as T4 *vs* TNM6th, and as T3 *vs* TNMc2008, respectively. The sixth (model-Td1) defined lateral pterygoid muscle involvement as T4 *vs* TNM6th, the seventh (model-Td2) defined it as T3 *vs* TNM6th and the eighth (model-Td3) defined it as T3 *vs* TNMc2008. The ninth (model-Te1) defined medial pterygoid muscle involvement as T4 *vs* TNM6th, and the last (model-Te2) defined it as T3 *vs* TNM6th. For N-classification, all four models were based on TNMc2008. The first (model-Na) classified positive RP-LN as stage N0, the second (model-Nb) disregarded ENS, the third (model-Nc) disregarded the size of positive cervical lymph nodes and the last (model-Nd) disregarded both ENS and cervical lymph node size.

The prognostic value of the 10 staging models for predicting FFS compared with the corresponding based TNM staging systems is presented in [Table 5](#tbl5){ref-type="table"}. For T-classification, both AIC and c-index revealed the poorer prognostic value of model-Ta1 *vs* TNM6th, model-Ta2 *vs* TNMc2008, and model-Tb *vs* model-Ta1; model-Tc1 was inferior to TNM6th, but model-Tc2 was superior to TNMc2008. In addition, the prognostic value of model-Td1 *vs* TNM6th and model-Td2 *vs* TNM6th was lower, but model-Td3 was superior to TNMc2008. Finally, both model-Td1 and model-Td2 were inferior to TNM6th. For N-classification, all models (model-Na, model-Nb, model-Nc and model-Nd) had a poorer prognostic value than TNMc2008, and model-Nd was inferior to both model-Nb and model-Nc.

The proposed staging criteria
-----------------------------

The above staging models failed to lead to superior stage migrations with reference to T-classification of TNM6th and N-classification of TNMc2008, and actually revalidated the superiority of these aspects of the two TNM staging systems. We therefore proposed to combine the T-classifications of the TNM6th and N-classifications of the TNMc2008 with slight modifications (merging category T2a and T2b into T2, and category N3a and N3b into N3). ([Table 1](#tbl1){ref-type="table"})

As indicated by the smaller AIC and larger c-index values, the clinical stage groups of the proposed staging criteria had superiority for predicting FFS in patients treated with IMRT compared with those of both TNM6th and TNMc2008 ([Table 5](#tbl5){ref-type="table"}). This observation was generally supported by the FFS curves (*P*~trend~\<0.001) and independent significance in multivariate analysis (adjusted HR 2.14, 95% CI 1.76--2.59, *P*\<0.001), despite the nonsignificant increases in risk of failure between certain adjacent staging categories (stage I *vs* II: the log-rank test *P*=0.069; adjusted HR 3.07, 95% CI 0.91--10.34, *P*=0.070; [Figure 1C](#fig1){ref-type="fig"} and [Table 6](#tbl6){ref-type="table"}). Specifically, for T-classification and N-classification categories, the proposed staging criteria showed to be significant predictor for FFS in univariate and multivariate analyses (T-classification: the log-rank test *P*~trend~\<0.001; adjusted HR 1.63, 95% CI 1.38--1.92, *P*\<0.001; N-classification: the log-rank test *P*~trend~\<0.001; adjusted HR 1.72, 95% CI 1.47--2.02, *P*\<0.001). When evaluating T-classification and N-classification as categorical variables, unfortunately, we observed no significant segregations of T1 *vs* T2 (*P*=0.063, [Figure 1A](#fig1){ref-type="fig"}) and N1 *vs* N2 (*P*=0.089, [Figure 1B](#fig1){ref-type="fig"}).

Discussion
==========

A recent study ([@bib32]) compared TNMc2008 with TNM7th in 816 Chinese patients from a single hospital. However, only 293 (35.9%) patients underwent IMRT and there were no stratification analyses according to radiation techniques, as there was significant higher local control rate using IMRT than CRT ([@bib18]). Secondly, the most recent revision of TNM7th ([@bib10]; [@bib17]; [@bib34]) was not applied properly, as medial and lateral pterygoid muscle involvement were not classified as T4. Moreover, unfortunately, the data set was so heterogeneous -- with a wide range of treatments, in particular the types of chemotherapy -- that credible conclusions were hard to draw without stratification analyses or Cox regression analyses. Lastly and most importantly, survival curves were delineated by T- or N-classification of the respective staging systems, the classification categories were compared using the log-rank test and then the superiority of a staging system was judged on the basis of significant separations of the curves. In fact, survival curves are significantly affected not only by stage classification itself, but also by prognostic factors such as the treatment approach (IMRT *vs* CRT ([@bib39]; [@bib18]; [@bib33]), no chemotherapy *vs* chemotherapy and the type of chemotherapy ([@bib2]; [@bib31])). Therefore, it is insufficient to determine which staging system has the highest prognostic value based on survival curves in terms of T- or N- stages alone, without considering other prognoses.

In contrast, in this study we enrolled a large number of MRI-based patients (*n*=2333), tested the staging systems in both the IMRT cohort (*n*=941) and CRT cohort (*n*=1392) and further validated the results in 1673 patients who were treated with either IMRT or CRT between 2005 and 2006 ([Table 2](#tbl2){ref-type="table"}). Secondly, we stratified the patients in each cohort by the major types of chemotherapy to eliminate the effects of chemotherapy heterogeneity ([Table 3](#tbl3){ref-type="table"}). In addition, stratified analysis on the patients\' characteristics, such as age and gender, was also performed ([Table 4](#tbl4){ref-type="table"}). In essence, all staging systems are mathematical models for use in the clinic, and their ability to correctly predict patient survival must be evaluated as a whole, rather than be partially assessed based on the magnitude of segregation of each stage or category, as in previous studies ([@bib24]; [@bib28]; [@bib21]; [@bib7]; [@bib32]; [@bib34]). Here, we scored the models according to their accuracy for predicting FFS in the same patients, and finally determined the superiority of the models -- staging systems -- according to AIC and c-index scores. In addition, patient characteristics, such as age and gender, were included in the calculation of AIC by Cox regression. Hence, our comparison of the staging systems is distinct to previous comparisons ([@bib21]; [@bib7]; [@bib32]; [@bib34]), and more accurately and fully indicates the superiority of T-classification in TNM6th for IMRT patients, T-classification in TNMc2008 for CRT patients and N-classification in TNMc2008 for all patients.

Considering previous controversial findings regarding the prognosis of certain structure features in TNM staging criteria, it is not unexpected to observe insignificant improvement of TNM7th over TNM6th or TNMc2008. Also, we further validated the results by staging models.

For the T-classification categories, previous studies ([@bib19]; [@bib24]; [@bib28]) found no significant differences in locoregional relapse-free survival (LRFS) between oropharynx and/or nasal cavity involvement and tumours confined to the nasopharynx; however, the poorer prognostic values of model-Ta1 *vs* TNM6th and model-Ta2 *vs* TNMc2008 suggest these features should not be categorised as stage T1, which is supported by the report from [@bib25]). A recent study ([@bib21]) even proposed downstaging of parapharyngeal extension to T1, but this recommendation was not supported by comparison of model-Ta1 with model-Tb. Another study ([@bib36]) concluded that anatomic masticator space involvement including the medial and lateral pterygoid muscles should be classified as stage T4, despite the fact that anatomic masticator space involvement was a significant independent prognostic factor for OS (*P*=0.02), but not LRFS (*P*=0.05) or DMFS in the same study. Our staging models (model-Td1, model-Td2, model-Td3, model-Te1 and model-Te2) also failed to improve prognostic value when pterygoid muscles involvement was classified as stage T4 or T3. In addition, there are discrepancies in categorising the paranasal sinuses between the UICC/AJCC and Chinese staging systems, but no studies had compared the prognostic value of this feature with other structures involved in T4. For the first time, model-Tc1 and model-Tc2 support the classification of paranasal sinus involvement as T3. In brief, our staging models for the T-classification category present concrete evidence of the advantages of T-classification in TNM6th without the new regrouping suggestions. The following reasons may explain the nonsignificant prognostic values of our models in contrast to previous studies ([@bib19]; [@bib24]; [@bib28]; [@bib36]; [@bib21]). Firstly, there were a limited number of cases with solely oropharynx and/or nasal cavity involvement; therefore, based only on the magnitude of segregation of the survival curves by the log-rank test ([@bib19]; [@bib24]; [@bib28]), significant differences were difficult to observe between these cases and those with tumours confined to the nasopharynx when both groups have such high survival rates. However, the slight differences between our models and TNM6th or TNMc2008 could be detected using the AIC and c-index values. Secondly, as IMRT provides better locoregional control than CRT ([@bib39]; [@bib18]; [@bib33]), it is reasonable that categorisation of the medial and lateral pterygoid muscles and paranasal sinuses as stage T4 did not improve prognostic values. The enhanced locoregional control offered by IMRT may also explain the phenomenon that TNM6th had the best prognostic value in the IMRT cohort, whereas TNMc2008 was superior in the CRT cohort and third cohort ([Table 2](#tbl2){ref-type="table"}). Furthermore, it is possible that the combination of IC plus CC and RT leads to an extremely high survival rate ([@bib16]), which may explain why TNM6th, rather than TNMc2008, had superior prognostic value in the IC plus CC sets of the CRT cohort and third cohort ([Table 3](#tbl3){ref-type="table"}). Because of the small proportion of patients (16.8%) treated with IMRT in the third cohort, its results were quite consistent with those of the CRT cohort.

For the N-classification categories, the MRI-based TNMc2008 was superior to the other systems as a whole, similar to the results of a previous study ([@bib32]). This result was not unexpected, considering that the palpation-based greatest dimension in TNM6th and TNM7th might contain subcutaneous tissues, and the fact that differences between clinicians and their characterisation of palpated tumours can result in chaotic diversity in prognostic assessment ([@bib20]; [@bib14]). Because of the uncertain prognostic value of RP-LN in previous studies ([@bib8]; [@bib26]; [@bib27]; [@bib30]; [@bib35]; [@bib37]; [@bib34]), we constructed the TNMc2008-based model-Na, and proved the importance of classifying positive RP-LN as N1. Secondly, because of the contradictory prognostic value of ENS in two studies ([@bib29]; [@bib22]), we constructed model-Nb, and found that ENS involvement should be classified as N2. In addition, the significance of cervical lymph node size determined by clinical palpation ([@bib20]; [@bib14]) or MRI ([@bib29]; [@bib22]) remained unclear; therefore, we constructed model-Nc, which demonstrated that lymph node size should not be disregarded in N-classification. In addition, the significant roles of ENS and lymph node size were revalidated by the poorer prognostic value of model-Nd as compared with model-Nb and model-Nc, which opposes the proposed N-classification system by [@bib22]). In summary, our staging models for the N-classification categories provided concrete evidence for the advantages of N-classification in TNMc2008 without the new regrouping suggestions.

Based on our comparison of TNM6th, TNM7th and TNMc2008, and the results of the staging models, we proposed to combine T-classification of TNM6th and N-classification of TNMc2008 ([Table 1](#tbl1){ref-type="table"}). The proposed staging system criteria led to a balanced clinical stage group distribution, and its clinical stage group had obviously superior prognostic value over TNM6th, TNM7th and TNMc2008 ([Table 5](#tbl5){ref-type="table"}), although no significant separation of risk of failure was observed between stage I and II (*P*=0.069, [Figure 1C](#fig1){ref-type="fig"}; *P*=0.070, [Table 6](#tbl6){ref-type="table"}).

The following limitations of this study deserve comment. Firstly, despite carefully designed step-by-step comparisons, this study was conducted on the basis of retrospective analysis of a large number of cases from a single centre; apart from 281 (16.8%) patients from the IMRT cohort, the validation (third) cohort consisted of all the same patients in the CRT cohort, instead of the other totally different population of patients. Therefore, the results of comparing the three staging systems and especially the prognostic value of the proposed staging system need to be further confirmed in a prospective multicentre clinical study. This is what we are planning at the moment. Secondly, because the RT techniques influenced the prognostic values of T-classification, and IMRT is now recommended for NPC, our proposed staging system was constructed and validated based on cases treated with IMRT; therefore, the T-classification and clinical stage groups of the proposed staging system may not be applicable to patients treated with CRT. Thirdly, there were nonsignificant segregations between certain adjacent stage categories using our proposed staging system. The small proportion of patients and low treatment failure rate in these stratums are important factors that should be considered. Also, this may be influenced by selection biases of patients. Further validations with data of patients from other centres are required. In addition, only the FFS was evaluated because of the large volume of data. But the events of FFS consist of locoregional relapse, distant metastasis or death, whichever is first. It is of excellence in reflecting the survival of patients, and commonly used as the primary end point in the recent randomised controlled trials. Finally, our proposed staging system had superior prognostic value over the three existing systems; unfortunately, it remains complicated. A simplified and superior staging system needs to be explored.

To summarise, TNM6th T-classification and TNMc2008 N-classification have superior prognostic value for patients treated with IMRT; TNMc2008 T-classification and N-classification were shown to be better than TNM6th and TNM7th for patients treated with CRT. In this study, TNM7th showed no significant improvement over TNM6th. In the IMRT era, combining TNM6th T-classification and TNMc2008 N-classification with slight modifications, we propose a new staging system: (1) T-classification: T1, nasopharynx; T2, oropharynx, nasal cavity, parapharyneal extension, medial and lateral pterygoid muscles; T3, bony structures and/or paranasal sinuses; T4, intracranial extension and/or cranial nerves, infratemporal fossa hypopharynx, orbit or masticatory space excluding medial and lateral pterygoid muscles; (2) N-classification: N0, none; N1, unilateral or bilateral retropharyngeal node(s), unilateral level Ib, II, III and Va involvement and the maximum diameter ⩽3 cm; N2, bilateral level Ib, II, III and Va involvement or the maximum diameter \>3 cm or with extranodal neoplastic spread; N3, level IV, Vb involvement; (3) stage group: I, T1N0M0; II, T1N1M0, T2N0-1M0; III, T1-2N2M0, T3N0-2M0; IVa, T1-3N3M0, T4N0-3M0; and IVb, any T any N M1. Thus, TNM classification for NPC can be unified internationally and its prognostic value improved.
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###### Classification criteria and stage groups by different systems for nasopharyngeal carcinoma

  **The 6th** **edition of UICC/AJCC**                                                                                                       **The 7th** **edition of UICC/AJCC**                                                                                                           **The Chinese 2008 staging system**                                                                                                                    **The proposed staging system**
  ------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------
  **T-classification**                                                                                                                                                                                                                                                                                                                                                                                                                             
  T1: nasopharynx                                                                                                                            T1: nasopharynx, oropharynx or nasal cavity                                                                                                    T1: nasopharynx                                                                                                                                        T1: nasopharynx
  T2a: oropharynx and/or nasal cavity T2b: parapharyneal extension                                                                           T2: parapharyneal extension                                                                                                                    T2: oropharynx, nasal cavity, parapharyneal extension                                                                                                  T2: oropharynx, nasal cavity, parapharyneal extension, medial and lateral pterygoid muscles
  T3: bony structures and/or paranasal sinuses                                                                                               T3: bony structures and/or paranasal sinuses                                                                                                   T3: skull base, medial pterygoid muscle extension                                                                                                      T3: bony structures and/or paranasal sinuses
  T4: intracranial extension and/or cranial nerves, infratemporal fossa hypopharynx, orbit or masticatory space[a](#t1-fn2){ref-type="fn"}   T4: intracranial extension and/or cranial nerves, hypopharynx, orbit or infratemporal fossa/masticatory space[b](#t1-fn3){ref-type="fn"}       T4: cranial nerves, paranasal sinuses, masticatory space excluding medial pterygoid muscle, intracranial (cavernous sinus, dural meninges) extension   T4: intracranial extension and/or cranial nerves, infratemporal fossa hypopharynx, orbit or masticatory space excluding medial and lateral pterygoid muscles
  **N-classification**                                                                                                                                                                                                                                                                                                                                                                                                                             
  N0: none                                                                                                                                   N0: none                                                                                                                                       N0: none                                                                                                                                               N0: none
  N1: unilateral node(s), ⩽6 cm in greatest dimension, above the supraclavicular fossa                                                       N1: unilateral cervical and/or unilateral or bilateral retropharyngeal node(s), ⩽6 cm in greatest dimension, above the supraclavicular fossa   N1a: retropharyngeal node(s) N1b: unilateral level Ib, II, III and Va involvement, and the maximum diameter ⩽3 cm                                      N1: unilateral or bilateral retropharyngeal node(s), unilateral level Ib, II, III, and Va involvement, and the maximum diameter ⩽3 cm
  N2: bilateral node(s), ⩽6 cm in greatest dimension, above the supraclavicular fossa                                                        N2: bilateral cervical node(s), ⩽6  cm in greatest dimension, above the supraclavicular fossa                                                  N2: bilateral level Ib, II, III and Va involvement, or the maximum diameter \>3 cm, or with extranodal neoplastic spread                               N2: bilateral level Ib, II, III and Va involvement, or the maximum diameter \>3 cm, or with extranodal neoplastic spread
  N3a: \>6 cm N3b: in supraclavicular fossa                                                                                                  N3a: \>6 cm N3b: in supraclavicular fossa                                                                                                      N3: level IV and Vb involvement                                                                                                                        N3: level IV and Vb involvement
  **Stage group**                                                                                                                                                                                                                                                                                                                                                                                                                                  
  I: T1 N0 M0                                                                                                                                I: T1 N0 M0                                                                                                                                    I: T1 N0 M0                                                                                                                                            I: T1 N0 M0
  IIa: T2a N0 M0 IIb: T1-2a N1 M0, T2b N0-1 M0                                                                                               II: T1 N1 M0, T2 N0-1 M0                                                                                                                       II: T1 N1a-1b M0, T2 N0-1b M0                                                                                                                          II: T1 N1 M0, T2 N0-1 M0
  III: T1-2b N2 M0, T3 N0-2 M0                                                                                                               III: T1-2 N2 M0, T3 N0-2 M0                                                                                                                    III: T1-2 N2 M0, T3 N0-2 M0                                                                                                                            III: T1-2 N2 M0, T3 N0-2 M0
  IVa: T4 N0-2 M0 IVb: any T N3 M0 IVc: any T, any N M1                                                                                      IVa: T4 N0-2 M0 IVb: any T N3 M0 IVc: any T, any N M1                                                                                          IVa: T1-3N3M0, T4 N0-3 M0 IVb: any T, any N M1                                                                                                         IVa: T1-3N3M0, T4 N0-3 M0 IVb: any T, any N M1

Abbreviations: AJCC=American Joint Committee for Cancer; UICC=International Union against Cancer.

Masticator space involvement denotes extension of tumour beyond the anterior surface of the lateral pterygoid muscle or lateral extension beyond the posterolateral wall of the maxillary antrum and the pterygomaxillary fissure.

Masticator space primarily consists of the muscles of mastication. Anatomically, the superficial layer of the deep cervical fascia splits to enclose the muscles of mastication to enclose this space. These muscles are the medial and lateral pterygoid, masseter and temporalis.

###### Comparison of TNM6th, TNM7th and TNMc2008 by the proportion of patient numbers allocated in each category and the prognostic value

                         **IMRT cohort (*****N*****=941)**   **CRT cohort (*****N*****=1392)**   **The third cohort (*****N*****=1673)**[a](#t2-fn2){ref-type="fn"}                                                                                                    
  ---------------------- ----------------------------------- ----------------------------------- -------------------------------------------------------------------- ---------- ----------- ----- ------ ------ ---------- ----------- ----- ------ ------ ---------- -----------
  **T-classification**                                                                                                                                                                                                                                                 
  TNM6th                                                                                                                                                              2585.367   0.6390385                       6007.313   0.6140549                       7232.252   0.6210207
  T1                     144                                 15.3                                90.5                                                                                        178   12.8   86.9                          212   12.7   87.1               
  T2a+T2b                231                                 24.6                                84.4                                                                                        377   27.1   77.8                          452   27.0   79.1               
  T3                     397                                 42.2                                75.6                                                                                        530   38.1   68.2                          638   38.1   68.8               
  T4                     169                                 18.0                                60.6                                                                                        307   22.1   59.7                          371   22.2   59.2               
  TNM7th                                                                                                                                                              2593.242   0.6226889                       6008.392   0.6137931                       7236.528   0.6170047
  T1                     154                                 16.4                                89.7                                                                                        200   14.4   86.8                          238   14.2   86.8               
  T2                     206                                 21.9                                84.0                                                                                        324   23.3   77.7                          390   23.3   79.2               
  T3                     321                                 34.1                                75.4                                                                                        405   29.1   68.3                          483   28.9   68.6               
  T4                     260                                 27.6                                66.9                                                                                        463   33.3   63.0                          562   33.6   63.0               
  TNMc2008                                                                                                                                                            2593.998   0.6237146                       5999.054   0.623547                        7224.797   0.627451
  T1                     144                                 15.3                                90.5                                                                                        178   12.8   86.9                          212   12.7   87.1               
  T2                     216                                 23.0                                83.8                                                                                        346   24.8   77.9                          416   24.9   79.5               
  T3                     352                                 37.4                                75.4                                                                                        496   35.7   70.9                          587   35.1   71.1               
  T4                     229                                 24.3                                66.0                                                                                        372   26.7   58.0                          458   27.4   58.5               
  **N-classification**                                                                                                                                                                                                                                                 
  TNM6th                                                                                                                                                              2588.700   0.6051181                       5997.412   0.6192496                       7231.989   0.6541163
  N0                     291                                 30.9                                86.0                                                                                        346   24.9   85.1                          439   26.2   84.9               
  N1                     396                                 42.1                                76.5                                                                                        642   46.1   70.6                          755   45.1   70.7               
  N2                     206                                 21.9                                74.5                                                                                        308   22.1   65.1                          368   22.0   66.5               
  N3a+N3b                48                                  5.1                                 45.5                                                                                        96    6.9    43.6                          111   6.6    45.2               
  TNM7th                                                                                                                                                              2585.758   0.6071424                       6000.594   0.6104974                       7233.640   0.6544887
  N0                     199                                 21.1                                89.1                                                                                        241   17.3   86.4                          308   18.4   86.5               
  N1                     488                                 51.9                                76.9                                                                                        747   53.7   72.4                          886   53.0   72.2               
  N2                     206                                 21.9                                74.6                                                                                        308   22.1   65.1                          368   22.0   66.5               
  N3a+N3b                48                                  5.1                                 45.5                                                                                        96    6.9    43.6                          111   6.6    45.2               
  TNMc2008                                                                                                                                                            2577.726   0.6297874                       5956.339   0.6533576                       7181.886   0.6933172
  N0                     215                                 22.8                                88.3                                                                                        255   18.3   86.0                          326   19.5   85.7               
  N1a +N1b               413                                 43.9                                78.8                                                                                        583   41.9   76.7                          694   41.5   76.8               
  N2                     235                                 25.0                                73.5                                                                                        434   31.2   64.5                          517   30.9   65.0               
  N3                     78                                  8.3                                 51.6                                                                                        120   8.6    38.7                          136   8.1    38.6               
  **Stage group**                                                                                                                                                                                                                                                      
  TNM6th                                                                                                                                                              2563.425   0.6668522                       5974.760   0.6385112                       7187.989   0.6466896
  I                      74                                  7.9                                 92.8                                                                                        71    5.1    94.3                          89    5.3    94.3               
  IIa+IIb                211                                 22.4                                88.8                                                                                        343   24.6   83.1                          408   24.4   84.4               
  III                    445                                 47.3                                78.3                                                                                        595   42.7   70.8                          715   42.7   71.3               
  IVa+IVb                211                                 22.4                                58.4                                                                                        383   27.5   57.1                          461   27.6   56.9               
  TNM7th                                                                                                                                                              2575.341   0.644973                        5977.867   0.6383058                       7196.383   0.6419891
  I                      64                                  6.8                                 94.9                                                                                        67    4.8    92.5                          84    5.0    92.8               
  II                     210                                 22.3                                87.7                                                                                        323   23.2   84.6                          385   23.0   85.5               
  III                    373                                 39.6                                77.9                                                                                        470   33.8   70.9                          562   33.6   71.6               
  IVa+IVb                294                                 31.2                                65.2                                                                                        532   38.2   60.8                          642   38.4   60.9               
  TNMc2008                                                                                                                                                            2592.678   0.651191                        5950.440   0.6593581                       7166.274   0.6618726
  I                      69                                  7.3                                 95.2                                                                                        60    4.3    93.3                          76    4.5    93.4               
  II                     184                                 19.6                                87.1                                                                                        274   19.7   87.3                          329   19.7   88.0               
  III                    394                                 41.9                                79.6                                                                                        600   43.1   73.9                          711   42.5   74.3               
  IVa                    294                                 31.2                                63.9                                                                                        458   32.9   55.4                          557   33.3   56.0               

Abbreviations: AIC=Akaike information criterion; AJCC=American Joint Committee for Cancer; c-Index=Harrell\'s concordance index; CRT=conventional radiotherapy; FFS= failure-free survival; IMRT=intensity-modulated radiotherapy; TNM=tumour node metastasis; TNM6th=the sixth edition of the UICC/AJCC TNM staging system; TNM7th=the seventh edition of the UICC/AJCC TNM staging system; TNMc2008=the Chinese 2008 Staging System for nasopharyngeal carcinoma; UICC=International Union against Cancer.

The third cohort involved 1673 patients from January 2005 to December 2006, consisting of 281 out of 1673 (16.8%) patients with IMRT and 1392 out of 1673 (83.2%) with CRT treatment.

The AIC was calculated in Cox proportional hazards regression model with age (continuous), gender, histological type and types of chemotherapy for the IMRT and CRT cohort, and also with radiation techniques for the third cohort.

###### Comparison of TNM6th, TNM7th and TNMc2008 in predicting failure-free survival in subgroups of chemotherapy

                          **IMRT cohort (*****N*****=941)**                **CRT cohort (*****N*****=1392)**               **The third cohort (*****N*****=1673)**[a](#t3-fn2){ref-type="fn"}   
  ---------------------- ----------------------------------- ------------ ----------------------------------- ----------- -------------------------------------------------------------------- -----------
  RT alone set                        (*n*=219)                                        (*n*=328)                                                       (*n*=396)                                
  **T-classification**                                                                                                                                                                         
  TNM6th                               303.375               0.6878003                  901.218               0.6621048                                 1050.234                               0.6715685
  TNM7th                               305.081               0.6824811                  900.059               0.6754977                                 1048.985                               0.6806435
  TNMc2008                             304.234               0.6817948                  896.791               0.6757416                                 1046.935                               0.6819199
  **N-classification**                                                                                                                                                                         
  TNM6th                               297.935               0.6708991                  901.584               0.6428327                                 1047.189                               0.6559189
  TNM7th                               294.478               0.6914036                  901.148               0.6381977                                 1047.472                               0.6471761
  TNMc2008                             291.221               0.7268360                  884.548               0.6748634                                 1027.730                               0.6870432
  IC set                                None                                           (*n*=281)                                                       (*n*=281)                                
  **T-classification**                                                                                                                                                                         
  TNM6th                                 ---                 ---                       1083.046               0.5527778                                 1083.046                               0.5527778
  TNM7th                                 ---                 ---                       1083.147               0.5549505                                 1083.147                               0.5549505
  TNMc2008                               ---                 ---                       1082.190               0.5685369                                 1082.190                               0.5685369
  **N-classification**                                                                                                                                                                         
  TNM6th                                 ---                 ---                       1075.827               0.5958746                                 1075.827                               0.5958746
  TNM7th                                 ---                 ---                       1075.021               0.5921342                                 1075.021                               0.5921342
  TNMc2008                               ---                 ---                       1061.585               0.6544279                                 1061.585                               0.6544279
  CC set                              (*n*=469)                                        (*n*=423)                                                       (*n*=526)                                
  **T-classification**                                                                                                                                                                         
  TNM6th                              1187.584               0.5851499                 1380.940               0.6128575                                 1771.414                               0.6162836
  TNM7th                              1189.337               0.5762542                 1380.908               0.6148377                                 1770.971                               0.6175654
  TNMc2008                            1191.628               0.5601325                 1376.665               0.6290704                                 1768.39                                0.6269293
  **N-classification**                                                                                                                                                                         
  TNM6th                              1178.929               0.5946466                 1383.465               0.6110286                                 1775.976                               0.5966301
  TNM7th                              1179.393               0.5852701                 1383.542               0.5968647                                 1777.221                               0.5876845
  TNMc2008                            1174.637               0.6141743                 1381.203               0.6186331                                 1770.424                               0.6183843
  IC+CC set                           (*n*=186)                                        (*n*=309)                                                       (*n*=414)                                
  **T-classification**                                                                                                                                                                         
  TNM6th                               489.122               0.6492647                 1291.418               0.5798540                                 1737.786                               0.5925196
  TNM7th                               493.670               0.6107353                 1294.298               0.5564794                                 1742.804                               0.5630775
  TNMc2008                             491.357               0.6338971                 1292.766               0.5727775                                 1739.083                               0.5865056
  **N-classification**                                                                                                                                                                         
  TNM6th                               497.512               0.52352941                1286.780               0.5974569                                 1739.399                               0.5786084
  TNM7th                               497.515               0.52294118                1288.125               0.5870632                                 1740.434                               0.5711631
  TNMc2008                             495.107               0.55088240                1270.375               0.6623397                                 1723.176                               0.6351195

Abbreviations: AIC=Akaike information criterion; AJCC=American Joint Committee for Cancer; CC=concomitant chemotherapy; c-Index=Harrell\'s concordance index; CRT=conventional radiotherapy; IC=induction chemotherapy; IMRT=intensity-modulated radiotherapy; RT=radiotherapy; TNM=tumour node metastasis; TNM6th=the sixth edition of the UICC/AJCC TNM staging system; TNM7th=the seventh edition of the UICC/AJCC TNM staging system; TNMc2008=the Chinese 2008 Staging System for nasopharyngeal carcinoma; UICC=International Union against Cancer.

The third cohort involved 1673 patients from January 2005 to December 2006, consisting of 281 out of 1673 (16.8%) patients with IMRT and 1392 out of 1673 (83.2%) with CRT treatment.

The AIC was calculated in Cox proportional hazards regression model with age (continuous), gender and histological type for the IMRT and CRT cohort, and also with radiation techniques for the third cohort. However, AIC and c-Index were not calculated in the RT plus CC and adjuvant chemotherapy set because of limited number of patients (*n*=67 in the IMRT cohort; *n*=51 in the CRT cohort).

###### Comparison of TNM6th, TNM7th and TNMc2008 in predicting failure-free survival in stratified analysis by age (⩽60 and \>60 years old) and gender

                          **IMRT cohort (*****N*****=941)**  **CRT cohort (*****N*****=1392)**    **The third cohort (*****N*****=1673)**[a](#t4-fn2){ref-type="fn"}                           
  ---------------------- ----------------------------------- ----------------------------------- -------------------------------------------------------------------- ----------- ------------ -----------
  Age ⩽60 years old                   (*n*=824)                                                                               (*n*=1234)                                           (*n*=1480)   
  **T-classification**                                                                                                                                                                         
  TNM6th                              2003.721               0.6325691                                                         4908.478                               0.6122992     5806.033   0.6209916
  TNM7th                              2010.644               0.6175336                                                         4917.419                               0.6090601     5810.901   0.6141826
  TNMc2008                            2009.290               0.6212674                                                         4907.862                               0.6194509     5798.277   0.6265544
  **N-classification**                                                                                                                                                                         
  TNM6th                              2004.321               0.6239475                                                         4901.345                               0.6239475     5804.875   0.6207027
  TNM7th                              2003.707               0.6172813                                                         4903.039                               0.6172813     5806.357   0.6149654
  TNMc2008                            1993.638               0.6658321                                                         4854.533                               0.6658321     5756.629   0.658327
  Age \>60 years old                  (*n*=117)                                                                               (*n*=158)                                            (*n*=193)    
  **T-classification**                                                                                                                                                                         
  TNM6th                               368.177               0.6676618                                                         712.375                                0.6245186     932.624    0.6293492
  TNM7th                               369.362               0.6462916                                                         710.596                                0.634387      931.752    0.6357388
  TNMc2008                             371.565               0.6296354                                                         710.525                                0.6413671     930.872    0.6368664
  **N-classification**                                                                                                                                                                         
  TNM6th                               375.870               0.6239475                                                          712.66                                0.6046213     934.879    0.5883806
  TNM7th                               372.357               0.6090601                                                         714.124                                0.5864891     935.447    0.5795747
  TNMc2008                             372.336               0.6658321                                                         711.049                                0.614249      928.596    0.627631
  Male                                (*n*=714)                                                                               (*n*=1054)                                           (*n*=1269)   
  **T-classification**                                                                                                                                                                         
  TNM6th                              2120.131               0.6392201                                                         4701.974                               0.6142803     5665.205   0.6212674
  TNM7th                              2124.745               0.6278203                                                         4702.009                               0.6141995     5668.907   0.6175336
  TNMc2008                            2126.928               0.6222739                                                         4690.542                               0.628093      5656.800   0.6325691
  **N-classification**                                                                                                                                                                         
  TNM6th                              2118.398               0.6239475                                                         4695.677                               0.6200693     5666.261   0.6170331
  TNM7th                              2114.491               0.6172813                                                         4699.371                               0.6098774     5666.916   0.6100415
  TNMc2008                            2107.173               0.6658321                                                         4660.241                               0.6546294     5626.74    0.6522923
  Female                              (*n*=227)                                                                               (*n*=338)                                            (*n*=404)    
  **T-classification**                                                                                                                                                                         
  TNM6th                               299.740               0.6435911                                                         917.401                                0.6128287     1071.017   0.6334405
  TNM7th                               303.410               0.6036224                                                         918.139                                0.6116616     1071.860   0.6270442
  TNMc2008                             300.965               0.6340996                                                         919.291                                0.6050162     1072.319   0.6283753
  **N-classification**                                                                                                                                                                         
  TNM6th                               304.453               0.6239475                                                         913.893                                0.6180926     1072.667   0.606749
  TNM7th                               305.631               0.6172813                                                         914.196                                0.6135194     1073.871   0.5981399
  TNMc2008                             304.022               0.6658321                                                         907.748                                0.6448647     1063.371   0.6396812

Abbreviations: AIC=Akaike information criterion; AJCC=American Joint Committee for Cancer; c-Index=Harrell\'s concordance index; CRT=conventional radiotherapy; IMRT=intensity-modulated radiotherapy; TNM=tumour node metastasis; TNM6th=the sixth edition of the UICC/AJCC TNM staging system; TNM7th=the seventh edition of the UICC/AJCC TNM staging system; TNMc2008=the Chinese 2008 Staging System for nasopharyngeal carcinoma; UICC=International Union against Cancer.

The third cohort involved 1673 patients from January 2005 to December 2006, consisting of 281 out of 1673 (16.8%) patients with IMRT and 1392 out of 1673 (83.2%) with CRT treatment.

The AIC was calculated in Cox proportional hazards regression model with histological type, types of chemotherapy and age (continuous) or gender for the IMRT and CRT cohort, and also with radiation techniques for the third cohort.

###### Comparison of TNM6th and TNMc2008 staging models and the proposed staging system in predicting failure-free survival of 941 patients in the intensity-modulated radiotherapy cohort

                                           **T-classification**   **N-classification**   **Stage group**                          
  ----------------------------- ---------- ---------------------- ---------------------- ----------------- ----------- ---------- -----------
  **Staging systems**                                                                                                             
  TNM6th                                   2585.367               0.6390385              2588.700          0.6051181   2563.425   0.6668522
  TNMc2008                                 2593.998               0.6237146              2577.726          0.6297874   2592.678   0.6511910
  **Staging models**                                                                                                              
  Model-Ta1                     TNM6th     2585.953               0.6381613              ---               ---         ---        ---
  Model-Ta2                     TNMc2008   2594.378               0.6229049              ---               ---         ---        ---
  Model-Tb                      TNM6th     2590.548               0.6304656              ---               ---         ---        ---
  Model-Tc1                     TNM6th     2588.819               0.6344470              ---               ---         ---        ---
  Model-Tc2                     TNMc2008   2592.163               0.6270070              ---               ---         ---        ---
  Model-Td1                     TNM6th     2590.323               0.6299291              ---               ---         ---        ---
  Model-Td2                     TNM6th     2585.388               0.6382018              ---               ---         ---        ---
  Model-Td3                     TNMc2008   2589.175               0.6320108              ---               ---         ---        ---
  Model-Te1                     TNM6th     2590.558               0.6260628              ---               ---         ---        ---
  Model-Te2                     TNM6th     2587.092               0.6348819              ---               ---         ---        ---
  Model-Na                      TNMc2008   ---                    ---                    2582.810          0.6203779   ---        ---
  Model-Nb                      TNMc2008   ---                    ---                    2600.696          0.6262281   ---        ---
  Model-Nc                      TNMc2008   ---                    ---                    2601.425          0.6271457   ---        ---
  Model-Nd                      TNMc2008   ---                    ---                    2601.719          0.6226484   ---        ---
  The proposed staging system              2585.367               0.6390385              2577.726          0.6297874   2557.782   0.6707051

Abbreviations: AIC=Akaike information criterion; AJCC=American Joint Committee for Cancer; c-Index=Harrell\'s concordance index; TNM=tumour node metastasis; TNM6th=the sixth edition of the UICC/AJCC TNM staging system; TNMc2008=the Chinese 2008 Staging System for nasopharyngeal carcinoma; UICC=International Union against Cancer.

The AIC was calculated in Cox proportional hazards regression model with age (continuous), gender, histological type and types of chemotherapy.

###### Independent significance of T-classification, N-classification and stage group of the proposed staging system in predicting failure-free survival of 941 patients in the intensity-modulated radiotherapy cohort in multivariate analyses[a](#t6-fn2){ref-type="fn"}

                         **T-classification**    **N-classification**  **Stage-group**                                                              
  ---------------------- ---------------------- ---------------------- ----------------- ------- --------------- --------- -------- --------------- ---------
  Age (continuous)       1.019                       1.006--1.031      0.003             1.020    1.008--1.033   0.002     1.018     1.006--1.031   0.003
  Gender                 0.491                       0.331--0.729      \<0.001           0.490    0.330--0.727   \<0.001   0.513     0.346--0.762   0.001
  Histological type      1.315                       0.551--3.142      0.537             1.363    0.570--3.258   0.486     1.567     0.654--3.753   0.314
  Chemotherapy           1.015                       0.928--1.110      0.740             1.003    0.916--1.098   0.943     1.012     0.923--1.109   0.799
  T-classification                                                                       1.648    1.389--1.956   \<0.001                             
  T1 (*n*=144, 15.3%)    1.000                                                           ---           ---       ---       ---            ---       ---
  T2 (*n*=231, 24.5%)    1.391                       0.731--2.647      0.315             ---           ---       ---       ---            ---       ---
  T3 (*n*=397, 42.2%)    2.245                       1.238--4.070      0.008             ---           ---       ---       ---            ---       ---
  T4 (*n*=169, 18.0%)    3.838                       2.076--7.094      \<0.001           ---           ---       ---       ---            ---       ---
  N-classification       1.718                       1.458--2.024      \<0.001                                                                       
  N0 (*n*=215, 22.8%)    ---                             ---           ---               1.000                             ---            ---       ---
  N1 (*n*=413, 43.9%)    ---                             ---           ---               1.725    1.086--2.742   0.021     ---            ---       ---
  N2 (*n*=235, 25.0%)    ---                             ---           ---               2.165    1.335--3.509   0.002     ---            ---       ---
  N3 (*n*=78, 8.3%)      ---                             ---           ---               6.173    3.627--10.507  \<0.001   ---            ---       ---
  Stage group                                                                                                                                        
  I (*n*=69, 7.3%)       ---                             ---           ---               ---           ---       ---       1.000                     
  II (*n*=191, 20.3%)    ---                             ---           ---               ---           ---       ---       3.074     0.914--10.341  0.070
  III (*n*=444, 47.2%)   ---                             ---           ---               ---           ---       ---       5.365     1.661--17.330  0.005
  IVa (*n*=237, 25.2%)   ---                             ---           ---               ---           ---       ---       12.066    3.705--39.292  \<0.001

Abbreviations: CI=confidence interval; HR=hazard ratio.

The T-classification was included as a covariate in analyses of the N-classification, and vice versa.

[^1]: These authors contributed equally to this work.
